Latest news

The Sciety syndicate and Segulah Medical Acceleration invest MSEK 106 in SAGA Diagnostics

2021-06-30

PRESS RELEASE. The Swedish diagnostics company SAGA Diagnostics, which develops ultrasensitive liquid biopsy tests for early detection of cancer relapse…

Read more

Company that develops novel osteoarthritis treatment raises capital with Sciety

2021-05-05

NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain…

Read more
Cartana__39

The investment syndicate

Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.

Read more about the Sciety investment syndicate and membership

Sciety life science day 1

Services we offer

Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.

Find out more about our services

Client testimonials_Sciety

What our clients say

“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”

Malte Kühnemund,  CEO Cartana

More client testimonials

Investment areas

Biotechnology

From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.

Medical technology

From clinical validation phase to expansion phase.

Pharmacology

From late preclinical phase to Phase II clinical trials. All therapeutic areas.

Diagnostics

From clinical validation to expansion phase. All indications.

ICT in healthcare

From pilot phase to expansion phase. Value-enhancing healthcare.

Health tech

From early sales to expansion phase. Preventive health and medical services.

Companies open for investments

We have one or more companies open for investments. Please login or create an account to learn more and invest.

Selection of executed investments

Synartro – 1

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Read more

Cavis Technologies

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.

Read more

Elypta

Elypta has developed a new method for early cancer diagnosis. Liquid Biopsy is a rapidly growing field that is expected to be of great importance for cancer diagnosis.

Read more

Athera Biotechnologies

The company is in Phase II with a pharmaceutical candidate for a life-threatening illness for which there are currently no sufficient therapies.

Read more